Kazia to present on Cantrixil at American Association for Cancer Research (AACR) 2019 Annual Meeting

SYDNEY, March 25, 2019 /PRNewswire/ — Australian oncology-focused biotech company Kazia Therapeutics Ltd (ASX: KZA, NASDAQ: KZIA) has been selected to present data from the Phase I study of Cantrixil in ovarian cancer at the American Association for Cancer Research (AACR) 2019 Annual Meeting. AACR’s Annual Meeting is one of the top-tier academic conferences worldwide and brings together around 20,000 representatives from academia, industry, government and advocacy organisations from across the globe. The meeting is being held from 29 March to 3 April at the Georgia World Congress Center in Atlanta, Georgia, USA. Clinical Program Director, Daniel Berg will be presenting ...

Gepostet in der Kategorie Wirtschaft (Anzahl der ansichten:) 4

Ähnlich Nachrichten